Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.

@article{Schindler2000StructuralMF,
  title={Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.},
  author={T. Schindler and W. Bornmann and P. Pellicena and W. Miller and B. Clarkson and J. Kuriyan},
  journal={Science},
  year={2000},
  volume={289 5486},
  pages={
          1938-42
        }
}
  • T. Schindler, W. Bornmann, +3 authors J. Kuriyan
  • Published 2000
  • Biology, Medicine
  • Science
  • The inadvertent activation of the Abelson tyrosine kinase (Abl) causes chronic myelogenous leukemia (CML. [...] Key Result Critical to the binding of STI-571 is the adoption by the kinase of an inactive conformation, in which a centrally located "activation loop" is not phosphorylated. The conformation of this loop is distinct from that in active protein kinases, as well as in the inactive form of the closely related Src kinases. These results suggest that compounds that exploit the distinctive inactivation…Expand Abstract
    1,665 Citations

    Topics from this paper

    STI-571: an anticancer protein-tyrosine kinase inhibitor.
    • R. Roskoski
    • Biology, Medicine
    • Biochemical and biophysical research communications
    • 2003
    • 101
    • PDF
    Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase
    • 714
    • PDF
    Breakthroughs and Views STI-571: an anticancer protein-tyrosine kinase inhibitor q
    • 1
    • PDF
    Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases.
    • 54
    A Myristoyl/Phosphotyrosine Switch Regulates c-Abl
    • 377
    A Novel Mode of Gleevec Binding Is Revealed by the Structure of Spleen Tyrosine Kinase*
    • 173
    • PDF
    Insights into selectivity of STI571 [GleevecTM] from X-ray crystallography
    • PDF
    Sti‐571 in Chronic Myelogenous Leukaemia
    • 27

    References

    SHOWING 1-10 OF 27 REFERENCES
    An intramolecular SH3-domain interaction regulates c-Abl activity
    • 213
    Structural basis of inhibitor selectivity in MAP kinases.
    • 366
    The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase.
    • 245
    Autoregulatory Mechanisms in Protein-tyrosine Kinases*
    • 306
    • PDF